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Abstract
Background: Immune checkpoint inhibitors, including antibodies against programmed death 1 (PD-1) and
cytotoxic T-lymphocyte antigen 4 (CTLA-4), are being used with increasing frequency for the treatment of cancer.
Immune-related adverse events (irAEs) including colitis, dermatitis, and pneumonitis are well described, but less
frequent events are now emerging with larger numbers of patients treated. Herein we describe the incidence and
spectrum of thrombocytopenia following immune checkpoint inhibitor therapy and two severe cases of idiopathic
thrombocytopenic purpura (ITP).
Case presentations: A 47-year-old female with recurrent BRAF mutant positive melanoma received combination
anti-PD-1 and anti-CTLA-4. Two weeks later, she presented with mucosal bleeding, petechiae, and thrombocytopenia
and was treated with standard therapy for ITP with steroids and intravenous immunoglobulin (IVIG). Her diagnosis was
confirmed with bone marrow biopsy, and given the lack of treatment response, she was treated with rituximab. She
began to have recovery and stabilization of her platelet count that ultimately allowed her to be retreated with PD-1
inhibition with no further thrombocytopenia. A second patient, a 45-year-old female with a BRAF wild-type melanoma,
received anti-PD-1 monotherapy and became thrombocytopenic 43 days later. Three weeks of steroid treatment
improved her platelet count, but thrombocytopenia recurred and required additional steroids. She later received
anti-CTLA-4 monotherapy and developed severe ITP with intracranial hemorrhage. Her ITP resolved after treatment of
prednisone, IVIG, and rituximab and discontinuation of checkpoint inhibition. In a retrospective chart review of 2360
patients with melanoma treated with checkpoint inhibitor therapy, <1% experienced thrombocytopenia following
immune checkpoint inhibition, and of these, most had spontaneous resolution and did not require treatment.
Conclusions: Thrombocytopenia, especially ITP, induced by immune checkpoint inhibitors appears to be an
uncommon irAE that is manageable with observation in mild cases and/or standard ITP treatment algorithms.
In our series, the majority of patients had mild thrombocytopenia that resolved spontaneously or responded
to standard corticosteroid regimens. However, in two severe cases, IVIG and rituximab, in addition to steroids,
were required. Checkpoint inhibition was resumed successfully in the first patient but rechallenge was not
tolerated by the second patient.
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Background
Immune checkpoint inhibitors, including antibodies
against programmed death 1 (PD-1) receptor, are quickly
becoming a staple in our arsenal of anti-cancer agents.
PD-1 signaling normally inactivates effector T cells when
bound to its ligands PD-L1 and PD-L2; thus, inhibition
of this pathway reinvigorates T cell antitumor responses
[1]. Nivolumab and pembrolizumab are monoclonal
antibodies that block PD-1 and have demonstrated
substantial benefit in melanoma, non-small cell lung
cancer, renal cell carcinoma, Hodgkin lymphoma, and
numerous other cancers [2].
Although inhibitors of PD-1 provide significant thera-
peutic benefit, many immune-related adverse events
(irAEs) have emerged with these therapies. The most
common irAEs include dermatologic toxicities and
thyroid dysfunction [3–5]. Other clinically significant
toxicities include colitis, hypophysitis, pneumonitis, and
hepatitis [4–7]. These events arise from dysregulation of
self-tolerance that is normally mediated by PD-1/PD-L1
interactions [8]. Additionally, anti-PD-1 (specifically
nivolumab) may be combined with ipilimumab, an
antibody against cytotoxic T-lymphocyte antigen 4
(CTLA-4), which when bound to costimulatory mole-
cules on antigen-presenting cells inactivates T cells.
Ipilimumab works synergistically with anti-PD-1 agents
and improves antitumor efficacy but also increases the
frequency and severity of irAEs [3, 5].
Recently, cases of hematologic irAEs were reported
with anti-PD-1 therapy, specifically autoimmune hemolytic
anemia and immune thrombocytopenic purpura (ITP)
[9–12]. Although cases of thrombocytopenia induced
by either pembrolizumab or ipilimumab alone have
been reported, its incidence, spectrum of severity, and
development of ITP have not been established [13, 14].
Given the rapid rise of immunomodulatory therapy use in
numerous cancers, there is a clear need to identify and
characterize these hematologic irAEs. Here, we report
two cases of severe ITP resulting from checkpoint
inhibitor therapy and the largest multi-institutional
case series of thrombocytopenia induced by check-
point inhibitor therapy.
Case presentations
A 47-year-old patient presented in 2011 with stage IIb
melanoma on her left forearm, which was removed by
wide local excision with a concurrent negative sentinel
lymph node biopsy. Four years later, she presented with
recurrent metastatic melanoma with a BRAFV600M muta-
tion. She initially responded to combination BRAF and
MEK inhibition but developed progressive disease within
five months. Two weeks later, she received her first infu-
sion of combination ipilimumab and nivolumab. She
developed bleeding from mucosal areas and petechiae
fifteen days following her first dose of combination check-
point inhibitor therapy with severe thrombocytopenia
(PLT < 5000/uL) and an elevated immature platelet frac-
tion of 15.4% (0.9 to 7.0% normal range). She had no
history of autoimmune or coagulation disorders, and the
remainder of her laboratory evaluation was unrevealing.
She was presumed to have new-onset ITP and was started
on methylprednisolone and intravenous immunoglobulin
(IVIG) (Fig. 1). After five days of steroids and IVIG with-
out significant improvement in her platelet count, a bone
marrow biopsy revealed a hypercellular marrow with
increased megakaryocytes (Fig. 2), further supporting the
diagnosis of ITP. Her treatment was escalated to weekly
rituximab with addition of a single dose of romiplostim, a
thrombopoietin analog. Seven days after steroids and
IVIG, and two days after rituximab, her platelet counts
began to improve, reaching normal range (137,000 to
397,000/uL) by one week, and she subsequently did not
require additional platelet transfusions (Fig. 1). Between
her second and third infusion of rituximab, she transiently
relapsed to a platelet count of 54,000/uL. She received
a total of four doses of rituximab in accordance with
standard therapy for ITP. Eight days after her last dose,
she was rechallenged with nivolumab monotherapy and
subsequently experienced a partial response with no
relapse of her ITP.
A second patient, a 45-year-old female with a BRAF
wild-type melanoma, received nivolumab as neoadjuvant
therapy in a clinical trial and became thrombocytopenic
(49,000/uL) 43 days later. She was asymptomatic and
was treated with prednisone for three weeks, with eleva-
tion of platelet levels to baseline (307,000/uL). However,
thrombocytopenia recurred with a platelet nadir of
28,000/uL, and she required an additional 12-week steroid
taper before her platelets recovered. She later developed
metastatic disease to the brain and underwent resection of
a large frontal lesion, as well as gamma knife irradiation to
several smaller lesions. Due to limited treatment options,
she was administered ipilimumab monotherapy, eight
months after receiving nivolumab. Within eight days, her
platelet count decreased from 75,000 to 8000/uL, and two
days later, she developed hemorrhage in her intracranial
metastasis with no detectable platelets. Her ITP ultimately
resolved after treatment with prednisone, IVIG, and ritux-
imab and discontinuation of ipilimumab.
To assess the incidence and clinical patterns of
thrombocytopenia, including potential cases of ITP,
following immune checkpoint inhibition, we performed
retrospective reviews of electronic medical records at
Georgetown Lombardi Cancer Center, Memorial Sloan
Kettering Cancer Center, Moffitt Cancer Center, MD
Anderson Cancer Center, and Vanderbilt-Ingram Cancer
Center. Patients with melanoma were included if they
experienced thrombocytopenia following treatment with
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a checkpoint inhibitor that was clinically diagnosed as
ITP or was not attributable to another cause. The pro-
ject was approved by IRBs of respective institutions with
waiver of consent. Statistical analysis was performed
using R version 3.3.0.
We assessed the frequency of thrombocytopenia in-
duced by treatment with checkpoint inhibitors across
these five institutions and identified 11 cases, several
presumed to be ITP based on clinical diagnostic criteria.
A total of 2360 patients with melanoma receiving check-
point inhibitor therapy were reviewed, suggesting an
incidence of well under 1%. These patients were Cauca-
sian men (58%) or women (42%) with melanoma; none
had a previous diagnosis of ITP or a history of
thrombocytopenia prior to initiation of treatment. Vari-
ous checkpoint inhibitor regimens were represented
(Table 1). The average time to onset of checkpoint
inhibitor-induced thrombocytopenia was 70 days (range,
12 to 173 days), and the average platelet count was
61,000/uL (range, <5000 to 104,000/uL) with an average
decrease of 70% from baseline (range, 38 to 99%). No
significant differences were found among the varying
checkpoint inhibitor regimens.
Of the 11 patients, four required immunosuppressive
treatment with corticosteroids, and two of those cases
were refractory to steroids. A higher percentage of
patients treated with ipilimumab (single agent or com-
bined with nivolumab) required immunosuppressive
treatment (75%, 3 of 4) compared to those treated with
anti-PD-1 monotherapy (14%, 1 of 7). The majority of
Fig. 1 Checkpoint inhibitor-induced ITP refractory to glucocorticoids subsequently responds to second-line treatment
Fig. 2 Bone marrow from patient with checkpoint inhibitor-induced
ITP before rituximab treatment. H&E stained section of the bone
marrow biopsy, 100 × magnification. The bone marrow is moderately
hypercellular for age with trilineage hematopoiesis and increased
megakaryocytes (black arrows) with a range of morphologies
and mild clustering. These findings, coupled with the patient’s
peripheral thrombocytopenia and elevated IPF, are compatible
with a diagnosis of ITP
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patients displayed no clinical signs or symptoms of
thrombocytopenia and required no therapies with spontan-
eous resolution (Table 1). Our first case described in detail
above had the most severe episode of thrombocytopenia
with confirmed ITP by bone marrow biopsy.
Conclusions
Thrombocytopenia, especially ITP, induced by immune
checkpoint inhibitors appears to be a relatively uncom-
mon irAE that is manageable with standard treatment
algorithms. In our series, the majority of patients had
mild thrombocytopenia that resolved spontaneously or
responded to standard corticosteroid regimens. How-
ever, in two severe cases, steroids, IVIG, and rituximab
were administered with ultimate recovery. In the first
case, nivolumab monotherapy was resumed with excel-
lent tolerance. On the other hand, the second patient
relapsed with subsequent immune checkpoint inhibition.
Primary ITP is a disorder caused by the formation of
autoantibodies targeting platelet antigens, leading to
thrombocytopenia [15]. ITP is a diagnosis of exclusion
and may be challenging given the lack of specific testing
and a wide differential diagnosis. ITP is thought to occur
after an inciting event activates or alters the immune
system, such as an infection, hematopoietic malignancy,
or pharmacologic immune checkpoint inhibition [16].
However, most cases are idiopathic in etiology. A major-
ity of acute cases (50–90%) are responsive to standard
corticosteroid and IVIG therapy, though a fraction of
cases require second-line treatment, usually involving a
combination of rituximab and a thrombopoietin agonist
[17]. In mouse models, there is loss of peripheral self-
tolerance through alteration of immune homeostasis and
evidence of regulatory T cell (Treg) deficiency associated
with ITP [18]. Comparison of bone marrow between
patients with ITP and normal donors revealed that those
with ITP have lower levels of Tregs and abnormal levels
of Th1 and Th17 cells [16]. Recent work demonstrated
that patients with chronic ITP exhibit lower levels of
PD-1 expression in total peripheral blood samples, com-
pared with healthy controls [19, 20]. A single case report
showed that a patient who developed nivolumab-
induced ITP had higher PD-1 expression on B cells [11].
Our experience suggests that thrombocytopenia, in-
cluding ITP, may rarely complicate immune checkpoint
inhibitor therapy but is usually mild and can resolve
spontaneously or with standard treatment algorithms.
The onset of ITP varies substantially, though a majority
occurs within the first 12 weeks after initiation of check-
point inhibition, consistent with other irAEs [21–23].
Although our observations on checkpoint inhibitor
rechallenge after resolution of ITP are limited, our
experience suggests that increased clinical vigilance
should be used, especially with ipilimumab.
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